Treatment
Guselkumab clinical trials
We’re tracking 41 recruiting studies that include Guselkumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07726888Recruiting
Guselkumab for moderate-to-severe ulcerative colitis
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
Wenzhou, ZhejiangAges 18 years+ - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07310095RecruitingPhase 4
Study of ustekinumab for Crohn's disease with loss of response
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
GuangzhouAges 18 years+ - NCT05858632RecruitingPhase 4
Study immune patterns during guselkumab skin response in psoriasis
This trial studies how the immune system changes in the skin after guselkumab treatment for psoriasis, including the scalp. You may be asked to meet certain scalp severity and medication safety rules.
San Francisco, CaliforniaAges 18 years+ - NCT06974474RecruitingPhase 4
Guselkumab for pain in psoriatic arthritis
This study tests if guselkumab can reduce pain and inflammation in people with psoriatic arthritis. You may join if standard treatments have not worked well enough or caused side effects.
Rome, ItalyAges 18–80 - NCT07487311Recruiting
Study of guselkumab plus JAK inhibitors for tough-to-treat IBD
This trial tests a combination of two medications—guselkumab and a JAK inhibitor—for people with inflammatory bowel disease that hasn't responded to other treatments. The goal is to see if this combination is safe and effective for patients with hard-to-control Crohn's disease or ulcerative colitis.
Hangzhou, ZhejiangAges 14–80 - NCT07246460Recruiting
Ultrasound and protein tests to see if guselkumab works for Crohn's
This study tests whether guselkumab (a targeted drug) can effectively treat Crohn's disease in the ileum (last part of the small intestine). You will have ultrasound scans and blood tests to measure your response, which may help find the right dose and monitor for bowel healing.
Calgary, AlbertaAges Up to 80 years - NCT07034664Recruiting
Ultrasound to predict Guselkumab response in Crohn's disease
This trial tests if a medication called Guselkumab can help people with moderate to severe Crohn's disease. It uses a special ultrasound to see how the bowel responds to treatment.
Changsha, HunanAges 18–80 - NCT06663332RecruitingPhase 3
Long-term study of guselkumab in children who previously took it
This study is a long-term follow-up for children who have already finished an earlier study of guselkumab, a medicine for skin conditions like psoriasis. It looks at whether staying on the medicine continues to be safe and helpful over time.
Atlanta, GeorgiaAges 3 years+ - NCT07141004RecruitingPhase 4
Study of guselkumab for psoriatic arthritis in Indian patients
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
AhmedabadAges 18 years+ - NCT05669833RecruitingPhase 3
Guselkumab versus golimumab for active psoriatic arthritis
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
Loxahatchee Groves, FloridaAges 18–80 - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Los Angeles, CaliforniaAges 2–17 - NCT07245394Recruiting
Switching to guselkumab for inflammatory bowel disease after ustekinumab
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
Calgary, AlbertaAges 18 years+ - NCT06563323RecruitingPhase 2
Testing Guselkumab for Pyoderma Gangrenosum
This study tests whether guselkumab (Tremfya) can help heal painful ulcers from Pyoderma Gangrenosum (PG). Participants must already be taking steroid medication and have a PG ulcer that is at least 4 cm².
Columbus, OhioAges 18–99 - NCT06586281Recruiting
Guselkumab for psoriasis arthritis and fatty liver
This study looks at whether the drug guselkumab can help people who have both psoriatic arthritis and non-alcoholic fatty liver disease (NAFLD). If you are starting guselkumab for your psoriatic arthritis and have a fatty liver, you may be able to join.
San Diego, CaliforniaAges Any age - NCT06651489RecruitingPhase 2
Guselkumab for Hailey-Hailey disease
This study tests the drug guselkumab to see if it can help control Hailey-Hailey disease, a rare skin condition. If you have moderate-to-severe HHD affecting multiple body areas, you may be able to join.
New Haven, ConnecticutAges 18–90 - NCT06916390RecruitingPhase 4
Testing guselkumab with antibiotics for chronic pouchitis
This study tests whether adding a medication called guselkumab to antibiotics can help people with chronic or recurring pouchitis, a condition that causes inflammation in the J-pouch after ulcerative colitis surgery. Participants will take antibiotics for the first 4 weeks and guselkumab as an injection over the course of the trial.
Leuven, Vlaams-BrabantAges 18 years+ - NCT07616687RecruitingPhase 4
Testing guselkumab to improve Crohn's disease control
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
AmiensAges 18 years+ - NCT07430319Recruiting
Real-life study of guselkumab dosing intervals
This trial is for people with skin psoriasis who are already taking guselkumab (Tremfya) and have their shots spaced 9 weeks or longer apart. Researchers will see how well the skin is controlled with this longer interval.
Nice, Alpes MaritimesAges 18 years+ - NCT07444060Recruiting
Guselkumab vs Ustekinumab for stricturing Crohn's disease
This study compares two medicines, Guselkumab and Ustekinumab, for people with Crohn's disease that causes narrowing (strictures) in the bowel. It aims to find which works better to improve symptoms and avoid the need for more procedures.
Hangzhou, ZhejiangAges 18–80 - NCT07532486Recruiting
Guselkumab dosing study for moderate-to-severe psoriasis
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
Hangzhou, ZhejiangAges 18 years+ - NCT07746583Recruiting
Switching from ustekinumab to guselkumab for psoriasis
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
BudapestAges 18 years+ - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT07606339Recruiting
Guselkumab for moderate-to-severe Crohn's or ulcerative colitis
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
ViennaAges 18 years+
What Guselkumab is being studied for
Conditions with recruiting Guselkumab studies.
Common questions
- Are there clinical trials studying Guselkumab?
- Yes. Clin2 currently lists 41 recruiting studies that include Guselkumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Guselkumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Guselkumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Guselkumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.